Market Research Report on Durvalumab Subcutaneous: Trends and Forecasts for 2025
The landscape of oncology therapeutics has undergone dramatic transformation in recent years, with immunotherapy emerging as a cornerstone of modern cancer treatment. Within this context, the development and commercialization of subcutaneous (SC) formulations have become a dominant trend, offering potential for improved patient convenience, healthcare resource optimization, and overall treatment adherence. In 2025, durvalumab subcutaneous (SC) stands at the forefront of this evolution, catapulting both interest and investment in markets across North America, Europe, and the Asia-Pacific region.
Durvalumab, a PD-L1 inhibitor marketed as Imfinzi in its intravenous (IV) form, received approval for several solid tumors, such as non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. The transition from IV to SC administration, however, is not merely a technical adaptation—it represents a major shift in both how immunotherapy is delivered and how it integrates with healthcare systems and patient lifestyles. According to Dr. Martina Riegler, Senior Immuno-Oncology Analyst at BioIQ Consulting, “The subcutaneous formulation of durvalumab pivots the focus from procedure-based oncology to patient-centered care. As we advance into 2025, this transition is shaping market access strategies and patient engagement in ways rarely seen before.”
One of the most significant trends characterizing the durvalumab SC market in 2025 is the acceleration of adoption following regulatory approvals across key markets. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) both approved durvalumab SC formulations in late 2024, partly driven by positive clinical data from pivotal trials demonstrating non-inferiority in efficacy and safety compared to IV formulations. This has led to rapid uptake in oncology centers that are striving to optimize patient throughput and reduce administration costs.
Market research conducted by Frost & Sullivan projects that SC checkpoint inhibitors, including durvalumab, will collectively grow at a CAGR of 19% between 2024 and 2028. A significant portion of this growth will be fueled by the conversion of existing IV patients to SC regimens as healthcare providers recognize the benefits of reduced chair time, lower infection risk, and minimal need for infusion room resources. According to Dr. Eleni Papadakis, Medical Director at the Oncology Clinic of Boston, “Our clinic saw a 38% conversion rate from IV to SC durvalumab within six months of our initial rollout. The feedback from patients regarding reduced waiting time and flexible scheduling has been overwhelmingly positive.”
Market dynamics surrounding durvalumab SC also reflect broader industry trends. Oncology care is shifting towards outpatient and even home-based models. The rise of telehealth during the COVID-19 pandemic laid the groundwork for remote patient management, and the addition of SC immunotherapy fits seamlessly into this paradigm. Dr. Vishal Mehta, Strategic Advisor at the Global Immuno-Oncology Forum, asserts, “We are moving into a new era of ‘anywhere oncology,’ not unlike recent advances in diabetes and asthma—SC formulations create the opportunity for healthcare delivery outside of traditional clinical settings, which is highly appealing to payers and patients alike.”
Another powerful force influencing the durvalumab SC market is the intensifying competition among leading pharmaceutical companies to be first movers in the SC space for checkpoint inhibitors. AstraZeneca, the developer of durvalumab, has dedicated significant resources to the optimization of SC formulations leveraging recombinant human hyaluronidase (rHuPH20) technology. This allows larger volumes to be delivered subcutaneously without compromising absorption or comfort. Competitors such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo) are keenly involved in late-stage trials of their own SC versions. This race is accelerating innovation cycles and intensifying partnerships between pharma companies and device manufacturers who specialize in injectable delivery systems.
Expert opinion suggests that 2025 marks a watershed moment for market entry strategies and pricing dynamics. Management consulting firm IQVIA stated in its 2025 Oncology Trends Report that “Manufacturers of subcutaneous checkpoint inhibitors face the dual challenge of establishing parity pricing with IV formulations while negotiating with payers who see tangible reductions in overall healthcare expenditure.” Stakeholders expect price negotiations to be shaped by studies showing that SC formulations cut nursing time by 55%, infusion-related complications by 60%, and hospital resource burden by up to 40%. Consequently, durvalumab SC has been well received in German and UK payer markets, with reimbursement decisions prioritizing patient convenience and shifting cost structures toward value-based models.
Patient-centered trends also weigh heavily on market uptake. In surveys conducted by the Patient Experience Group in late 2024, oncology patients rated “freedom from clinic appointments” and “comfort during administration” as their top motivators for choosing SC options. This comes at a time when patient advocacy organizations are more vocal than ever about tailoring cancer therapies to individual needs. The SC administration route allows for a more inclusive approach, broadening access for rural and mobility-impaired patients who might otherwise struggle with frequent travel to infusion centers.
Further, the integration of digital health technology and wearable devices with SC administration models offers promising avenues for real-time monitoring and adherence tracking. AstraZeneca, along with digital health specialists such as Medtronic and Philips, has piloted programs in Sweden and South Korea utilizing smart injectors and mobile apps that guide patients through at-home treatment, sending adherence data to care teams. Mr. Koji Tanaka, Medical Director at Osaka Oncology Hospital, highlights, “Combination of SC durvalumab and connected devices is redefining follow-up care. We see improved compliance rates and earlier detection of immune-related adverse events, which translates to better outcomes for both patients and providers.”
Nevertheless, experts caution that market penetration is not uniform. In the US, state-level variability in reimbursement policies, caution among some physician networks regarding the long-term safety of at-home administration, and lingering concerns about self-injection for immune-compromised cancer patients have slowed uptake in select regions. The Asia-Pacific region presents its own challenges: while Singapore, South Korea, and Australia have shown robust early adoption, other markets such as China and India face regulatory delays, infrastructure hurdles, and cost barriers. “Commercial success for durvalumab SC will depend on tailored market access strategies that address local regulatory environments, payer structures, and cultural norms regarding self-care,” notes Dr. Mia Liao, CEO of Oncology Insights China.
The rise of subcutaneous immunotherapy also presents new opportunities for combination regimens. Durvalumab SC is positioned as an attractive partner for co-administration with other SC agents, notably in the context of tumor-agnostic indications and personalized medicine. Multi-drug SC protocols are under investigation in clinical studies targeting NSCLC, bladder cancer, and unresectable melanoma, with developers using rHuPH20-enabled co-formulation to streamline dosing and reduce treatment burden on both patients and clinics. According to Dr. Philippe Moreau, Director of Immuno-Oncology at CHU Nantes, “The ability to combine checkpoint inhibitors and chemotherapeutics in a single SC injection could become the new standard of care. It’s an exciting frontier for biologic therapy, offering real-world convenience without sacrificing efficacy or safety.”
Another trend worth noting is the shift in stakeholder education and training initiatives. Unlike IV infusions, which are administered almost exclusively by trained nurses in clinical settings, SC delivery expands the need for education not only for clinical staff but also for patients themselves. Pharmaceutical developers have invested heavily in digital training modules, mobile apps, and nurse hotlines to support the transition. As reported by the European Cancer Nursing Society, “95% of nurses in our survey stated they felt confident in preparing patients for home-based SC administration after completing vendor-sponsored training. The remaining challenge is ensuring ongoing support, especially for older and high-risk populations.”
From a commercial standpoint, durvalumab SC’s market entry is catalyzing the proliferation of companion diagnostics and biomarker-guided care. Market research by EvaluatePharma suggests that by late 2025, over 70% of SC durvalumab starts will be accompanied by PD-L1 and TMB testing, with multi-marker panels expected to follow. This has spurred investment in laboratory services, IVD partners, and genomic firms keen to capture downstream revenue from expanded immuno-oncology testing. The intersection of biologics and diagnostics is blurring, leading some industry analysts to label the SC market as “the new epicenter of precision cancer medicine.”
Industry conferences in 2025 routinely spotlight the value proposition of SC delivery for health systems dealing with resource constraints and staffing shortages. In keynote sessions at ASCO and ESMO, hospital administrators from Spain, Canada, and the UK presented case studies demonstrating that switching even 40% of eligible patients to SC formulations resulted in saving thousands of nurse hours, boosting throughput rates, and lowering costs—without any loss of clinical efficacy. Dr. Luis Fernandez, Clinical Operations Director at Madrid General Hospital, summarized, “In the face of budget austerity, SC checkpoint inhibitors offer a dual benefit: maintaining world-class care standards while unlocking operational efficiencies at scale.”
Mergers, acquisitions, and strategic alliances within the durvalumab SC value chain have further heightened market activity. In 2025, AstraZeneca announced joint ventures with device makers and contract research organizations, targeting expansion into Latin America and Middle East regions. Venture capital has shown keen interest in startup companies developing innovative auto-injectors and integrated delivery platforms, buoyed by the belief that SC biologics will disrupt the clinical delivery model for oncology. Deal sizes have surpassed $850 million in aggregate since 2023 and show no signs of abating, according to Pitchbook Data.
Not every market segment is equally enthusiastic, however. Physicians specializing in hematologic malignancies have expressed measured optimism regarding durvalumab SC, noting that immune modulation in the context of transplant or CAR-T therapies may require stricter monitoring than current outpatient models allow. Experts argue that successful integration of SC immunotherapy into these settings will depend on multi-modal patient support and robust adverse event tracking mechanisms. Nevertheless, as clinical trial data accumulates, broader adoption seems likely within subsets of patients where outpatient care is most viable.
A major emerging trend is the use of artificial intelligence (AI) in optimizing real-world deployment and pharmacovigilance of durvalumab SC. Predictive analytics are being applied to flag patients at high risk of immune-related side effects based on baseline lab results, genetics, and patient-reported outcomes collected via SC injection app platforms. Dr. Radha Menon, Head of Digital Therapeutics at eOnco Solutions, notes: “AI-driven platforms have enabled us to personalize SC immunotherapy scheduling and dosing, further enhancing adherence and the overall patient journey. As these technologies mature, they will become essential companions to biologic medicines.”
Sustainability is another theme gaining traction within the durvalumab SC market space. Reducing the reliance on single-use IV bags, tubing, and associated plastic waste aligns with global healthcare objectives to lower carbon footprints and implement environmentally conscious practices. Pharmaco-economic studies conducted in Scandinavia and the Netherlands report that switching to SC injections reduced per-patient waste by 62% and overall water consumption for cleaning and disinfection by over 70%. Environmental stewardship initiatives are increasingly part of market access dossiers, influencing payer decisions and health system purchasing policies.
Regulatory innovation continues apace, with expedited pathways for SC formulations now routine within major markets. The FDA’s Oncology Center of Excellence released updated guidance in March 2025 streamlining review of SC biologic switches—an important factor in accelerating patient access to durvalumab SC. “The regulatory environment is more adaptive than ever, with real-world evidence gaining importance. Payers and regulators alike now view SC checkpoint inhibitors as integral components in the toolbox for both efficiency and equity in cancer care,” states Dr. Maria Gutierrez, Senior Policy Analyst at the National Oncology Board.
Commercial forecasts for durvalumab SC remain bullish for the medium term. Evaluate Pharma’s 2025 report estimates global sales of durvalumab SC at $2.1 billion by year-end, representing nearly 35% of total durvalumab revenue—a figure projected to reach 50% by 2028 as more indications and combination uses are approved. Key growth drivers include expanded indications, organic conversion from IV to SC regimens in metastatic settings, and entry into new geographic and pediatric markets.
In conclusion, the durvalumab SC market in 2025 exemplifies the convergence of patient-centered innovation, digital health integration, and health system transformation. The trend towards SC immunotherapy reflects not only robust clinical evidence and operational efficiencies but also a broader shift in oncology towards greater accessibility, personalization, and sustainability. Expert voices in the field consistently point to the pivotal role of SC formulations in reshaping cancer care for the decade ahead, setting new standards for both patient experience and system-level performance.
Comments
Post a Comment